Market Signal Briefing

The Bitcoin price was gradually coiling up, eyeing $130,000, and forming consecutive higher highs and lows. The rally paused when US President Donald Trump reignited trade tensions with China by imposing 100% tariffs on select goods. This triggered a sharp market sell-off, leading to over $20 billion in liquidations within hours. Now that the President has signaled a willingness to negotiate, the BTC price is witnessing a measured recovery.

Institutional interest in Bitcoin continues to grow, with Trump’s own company reportedly accumulating BTC alongside giants like MicroStrategy and MetaPlanet. Since then, Bitcoin’s price action has steadied, avoiding another single-day crash. As US political and economic dynamics evolve, Bitcoin appears closely tethered to these shifts—leaving investors to wonder: Is it time to trust the recovery and invest in Bitcoin now?

Behind the Crash: What Really Triggered Bitcoin’s Sudden Fall?While the US–China tariff tension served as the official spark, several on-chain and trading patterns suggest that the recent Bitcoin and crypto market crash may have had deeper roots. Analysts point to a series of suspicious moves that indicate the sell-off could have been strategically orchestrated rather than purely reactionary.

Whale Activity Before the Drop: Blockchain trackers flagged a Satoshi-era wallet that reportedly opened a $1.1 billion short position hours before the tariff announcement. This timing has fueled strong speculation that some large players anticipated the news in advance.Exchange Mechanics & Forced Liquidations: The crash triggered over $20 billion in liquidations, exposing the vulnerability of highly leveraged traders. Some suggest exchanges may have let liquidation cascades run deep to flush overleveraged positions.Insider-Like Trading Patterns: The simultaneous surge in short open interest across major derivatives platforms points toward coordinated market positioning—a move more typical of insiders than retail participants.Despite the theories, none of these claims are proven. Yet, they highlight a critical reality—Bitcoin’s price remains heavily influenced by powerful hands and centralized liquidity flows, not just global headlines. 

Can Bitcoin (BTC) Price Sustain Recovery Toward $130K?The crypto markets faced one of the largest liquidations last week, which has changed the trade dynamics for the BTC price for a while. The token quickly dropped heavily, breaking the critical support zone between $119,850 and $120,600. The ascending support did its job well and prevented the price from excessively bearish action. However, it would be interesting to witness how the recovery will unfold hereafter, as the bullish action remains a little vague at the moment. 

As seen in the above chart, the BTC price remains within a bullish trajectory regardless of the recent market crash. The price is trading between the 50-day & the 200-day MA which has been acting as the interim resistance & support level. Although the RSI has triggered a rebound, it quickly displayed a bearish divergence before rising beyond the average range. This suggests the indecisiveness among the bulls, which may further compel the price to drop back to the local support. 

Wrapping it Up!No doubt the Bitcoin bulls prevented the price from plunging below the psychological barrier at $100K, but the recovery has also been challenged by the bears. Since August, the price has been struggling to hold strongly above $117,000 which has now become one of the important zones to secure. Moreover, the latest rise above this zone also resulted in a market crash which brings us to the conclusion that the investors need to watch out closely before investing in Bitcoin at the moment.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

The crypto market has seen a rollercoaster week, but prices are finally bouncing back. Bitcoin has climbed more than 4% in the past 24 hours, trading around $114,662, while Ethereum surged over 10% to $4,133.

The rebound followed Donald Trump’s recent statement aimed at easing global worries about the U.S.-China trade tensions.

 “We don’t want to hurt China, we want to work with them,” Trump said

After a sharp sell-off hit both stock and crypto markets earlier this week.

Trump Becomes the Largest Bitcoin Whale Donald Trump has emerged as one of the largest Bitcoin holders in the world. According to Forbes, Trump indirectly owns about $870 million worth of Bitcoin through his 41% stake in Trump Media & Technology Group, the parent company of Truth Social.

Earlier this year, Trump Media made headlines by investing $2 billion in Bitcoin, using funds raised from stock and debt sales. The move echoes MicroStrategy’s Bitcoin investment strategy, led by Michael Saylor. Despite recent market volatility, Trump Media’s Bitcoin holdings have become its strongest-performing asset, signaling growing confidence in digital currencies.

From Bitcoin Critic to SupporterTrump’s views on Bitcoin have changed dramatically over time. Back in 2019, he criticized it as “highly volatile” and “based on thin air.” But today, he has taken a completely different tone.

Since returning to the office, Trump has voiced support for blockchain innovation in the U.S., pushing policies designed to make the country a leader in crypto development. His administration recently introduced the GENIUS Act, aimed at boosting research and development in blockchain and digital asset technologies.

With Trump’s growing influence in crypto and whales making bold moves, the market faces a critical moment. Will Bitcoin continue its upward trend, or is another correction on the horizon?

For now, all eyes remain on Trump’s next statements and the broader crypto market recovery after trade war fears.

Never Miss a Beat in the Crypto World!Stay ahead with breaking news, expert analysis, and real-time updates on the latest trends in Bitcoin, altcoins, DeFi, NFTs, and more.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Disclaimer: I am not an investment advisor, and this article is not meant to be a recommendation for the purchase or sale of stock. Investors are advised to review all company documents and press releases to see if the company fits its own investment qualifications.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Quanex Building Products Corporation (NYSE: NX) between December 12, 2024 and September 5, 2025, both dates inclusive (the “Class Period”), of the important November 18, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Quanex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Quanex class action, go to https://rosenlegal.com/submit-form/?case_id=45157 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Quanex’s procedures and policies regarding tooling and equipment maintenance in its Tyman Mexico facility were significantly “underinvested”; (2) as a result, Quanex’s tooling and equipment conditions had significantly degraded to near “catastrophic” levels; (3) as a result of the foregoing, Quanex was likely to incur significant costs, “pushing out the timing” of expected benefits from the Tyman integration; (4) Quanex had previously identified the foregoing issues; and (5) as a result of the foregoing, defendants’ positive statements about Quanex’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Quanex class action, go to https://rosenlegal.com/submit-form/?case_id=45157 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Palantir's frothy valuation isn't for everyone.

Palantir Technologies has been one of the most dynamic -- and controversial -- stocks in the market for the last couple of years. Palantir's extraordinary run includes a 2,130% gain over the last three years. Had you invested $10,000 into Palantir stock then, you'd be sitting on a nest egg of $223,000 (at the time of this writing).

While the data mining company's growth is impressive and it has its bulls -- including me -- the stock's valuation is admittedly out of hand. Palantir stock has a trailing price-to-earnings (P/E) ratio of an eyewatering 623, and a forward P/E of 217. The price-to-sales (P/S) ratio is hard to stomach as well, coming in at 137.

I'm a believer in the Palantir growth story, and I've long said that the market doesn't yet recognize the stock's true potential. But Palantir's not for everyone. If you're looking for some outstanding artificial intelligence (AI) stocks that don't carry the baggage that Palantir sports, here are two to consider right now.

Image source: Getty Images.

1. Advanced Micro Devices
Advanced Micro Devices (AMD -7.78%) is seen as second fiddle to the biggest chipmaker in the bunch, Nvidia. But it's quietly having a better year. AMD stock is up 90% so far this year, compared to Nvidia's 43% gain.

A huge percentage of that gain has been this month, after AMD and OpenAI announced a deal that would see the maker of ChatGPT purchase 6 gigawatts of AMD's Instinct MI450 graphics processing units (GPUs) to power several generations of OpenAI infrastructure. AMD issued a warrant that allows OpenAI to buy up to 160 million shares of stock, which could mean a 10% stake in the company.

Wedbush analyst Dan Ives, who is one of the most well-known analysts covering the AI and tech space, called the deal a "huge vote of confidence" for AMD.

"With a 10% stake in AMD, this quickly brings ... [AMD CEO] Lisa Su and AMD right into the core of the AI chip spending cycle and is a huge vote of confidence from OpenAI and ... [OpenAI CEO Sam] Altman. Any lingering fears around AMD should now be thrown out the window," he wrote in a social media post. "Major validation moment for AMD."

He's right. OpenAI is a huge player in the AI space, and its partnership with AMD is an endorsement of the company's GPUs. Even though Nvidia has the lion's share of the market, AMD now has an opportunity. And it's cheap, compared to Palantir, with a trailing P/E of 101 and a forward P/E of 28.5.

2. CoreWeave
However, GPUs are only half the story. Companies also need the horsepower to run AI applications, delivered at scale. And that's where CoreWeave (CRWV -3.32%) comes in.

CoreWeave is a cloud computing company that rents its Nvidia-supplied GPUs and cloud infrastructure to companies and developers who are working on AI and machine learning projects. Microsoft has been CoreWeave's biggest client, accounting for 62% of its revenue in 2024. Nvidia is also a key partner, holding 24.3 million shares, and CoreWeave also has $22.4 billion in deals with OpenAI.

The fast-growing company has 33 data centers across the country, with a revenue backlog of $30.1 billion, up 86% from a year ago. The company's revenue in the second quarter was $1.21 billion, up from $395.3 million a year ago. "We are scaling rapidly as we look to meet the unprecedented demand for AI," CEO Michael Intrator said.

CoreWeave isn't making a profit yet, but the company's growth is impressive. The stock is up 250% so far this year, and its forward price-to-sales ratio of 13 is much more palatable than Palantir's 104.4.

The bottom line
I still like Palantir and am holding my position. But not every AI stock investor is OK with a nosebleed premium, so AMD and CoreWeave are compelling alternatives. AMD has been validated as a key AI player, and CoreWeave is building infrastructure and making high-quality AI capacity widely available. Together, they are a great way to invest in AI.

Patrick Sanders has positions in Nvidia and Palantir Technologies. The Motley Fool has positions in and recommends Advanced Micro Devices, Microsoft, Nvidia, and Palantir Technologies. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.

The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapies

October 13, 2025 00:00 ET

 | Source:

HUTCHMED (China) Limited

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 13, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) announces results from the FRUSICA-2 registration clinical trial of the fruquintinib and sintilimab combination for the treatment of patients with locally advanced or metastatic renal cell carcinoma. Results of the Phase III part of the study will be presented on Friday, October 17, 2025 during the European Society for Medical Oncology (“ESMO”) Congress in Berlin, Germany.

FRUSICA-2 is a randomized, open-label, active-controlled registration study evaluating the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy for the second-line treatment of advanced renal cell carcinoma (NCT05522231). A total of 234 patients were randomized into a group that received fruquintinib plus sintilimab combination therapy, or into a group that received axitinib or everolimus monotherapy. As of the progression free survival (“PFS”) final analysis cutoff of February 17, 2025, the median follow-up was 16.6 months.

The median PFS as assessed by blinded independent central review (BICR) was 22.2 months with fruquintinib plus sintilimab, compared to 6.9 months with axitinib/everolimus (stratified hazard ratio [HR] 0.373; stratified log-rank p<0.0001). The objective response rate (ORR) was 60.5% vs 24.3% (Odds Ratio 4.622, p<0.0001), and the median duration of response (DoR) was 23.7 vs 11.3 months, respectively. Overall survival data were still evolving at the time of data cutoff with maturity of approximately 20%. Efficacy benefits were observed in all prognostic risk groups, as defined by the International mRCC Database Consortium (IMDC) criteria.

The safety profile of the fruquintinib and sintilimab combination was tolerable and consistent with the known profiles of each individual treatment. Treatment-emergent adverse events (TEAEs) of grade 3 or above occurred in 71.4% of patients in the fruquintinib plus sintilimab group compared to 58.8% for patients in the axitinib/everolimus group.

“The FRUSICA-2 trial results provide compelling evidence that fruquintinib and sintilimab may offer a valuable new treatment option for patients with advanced renal cell carcinoma,” said Professor Dingwei Ye of Fudan University Shanghai Cancer Center and the co-leading Principal Investigator of the FRUSICA-2 study. “These findings show the combination’s potential to address a critical unmet need for this patient population, delivering consistent benefits across varied patient profiles and prognostic risk groups.”

“The FRUSICA-2 study suggests that fruquintinib and sintilimab could play a meaningful role in shaping second-line treatment strategies for advanced renal cell carcinoma,” said Professor Zhisong He of Peking University First Hospital and the co-leading Principal Investigator of the FRUSICA-2 study. “These results point to the combination’s potential to enhance clinical outcomes, providing a new option for managing this challenging disease.”

Supported by data from FRUSICA-2, a New Drug Application (NDA) for the combination of fruquintinib and sintilimab in patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment has been accepted for review by the China National Medical Products Administration (NMPA).

About Kidney Cancer and Renal Cell Carcinoma
It is estimated that approximately 435,000 new patients were diagnosed with kidney cancer worldwide in 2022.1 In China, an estimated 74,000 new patients were diagnosed with kidney cancer in 2022.2 Approximately 90% of kidney tumors are renal cell carcinoma.

The safety and efficacy of fruquintinib for the investigational uses discussed above have not been established and there is no guarantee that it will receive health authority approval or become commercially available in any country for the uses being investigated.

About Fruquintinib
Fruquintinib is a selective oral inhibitor of all three vascular endothelial growth factor receptors (“VEGFR”) -1, -2 and -3. VEGFR inhibitors play a pivotal role in inhibiting tumor angiogenesis. Fruquintinib was designed to limit off-target kinase activity and improve drug exposure to achieve sustained target inhibition.3

Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE®.  It is approved for the treatment of patients with metastatic colorectal cancer who have previously received fluoropyrimidine, oxaliplatin and irinotecan-based chemotherapy, and those who have previously received or are not suitable to receive anti-VEGF therapy or anti-epidermal growth factor receptor (EGFR) therapy (RAS wild-type) in China. The combination of fruquintinib and sintilimab has received conditional approval in China for the treatment of patients with advanced pMMR endometrial cancer who have failed prior systemic therapy and are not candidates for curative surgery or radiation.

Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA®.

About HUTCHMED
HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of fruquintinib, the further clinical development for fruquintinib, its expectations as to whether any studies on fruquintinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fruquintinib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of fruquintinib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products such as sintilimab as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries+852 2121 8200 / [email protected]  Media Enquiries FTI Consulting –+44 20 3727 1030 / [email protected] Atwell / Alex Shaw+44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)Brunswick – Zhou Yi+852 9783 6894 (Mobile) / [email protected]  Panmure LiberumNominated Advisor and Joint BrokerAtholl Tweedie / Emma Earl / Rupert Dearden+44 20 7886 2500  CavendishJoint BrokerGeoff Nash / Nigel Birks+44 20 7220 0500  Deutsche NumisJoint BrokerFreddie Barnfield / Jeffrey Wong / Duncan Monteith+44 20 7260 1000   ____________________________
1   The Global Cancer Observatory, kidney cancer fact sheet. https://gco.iarc.who.int/media/globocan/factsheets/cancers/29-kidney-fact-sheet.pdf. Accessed February 19, 2025.
2   The Global Cancer Observatory, China fact sheet. https://gco.iarc.who.int/media/globocan/factsheets/populations/160-china-fact-sheet.pdf. Accessed February 19, 2025.
3   Sun Q, et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45. doi: 10.4161/15384047.2014.964087.

Empowering insurers with smart automation and AI to modernize operations, enhance decision-making, and drive growth

, /PRNewswire/ - DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services provider, today announced the launch of DXC Assure Smart Apps, a new suite of AI-powered, workflow-driven applications designed to transform how insurers engage with customers, brokers, and advisors. Built for speed, precision, and flexibility, Assure Smart Apps combine intelligent automation with modular innovation to help insurers modernize operations and improve performance, all while leveraging existing systems.

DXC Launches Assure Smart Apps to Accelerate AI-Driven Innovation in the Insurance Industry (CNW Group/DXC Technology Services, LLC)

As insurers look to adopt AI and accelerate growth while managing costs and complexity, DXC Assure Smart Apps help insurers implement AI-driven solutions efficiently. The suite fully integrates with insurers' core systems through industry-leading cloud capabilities powered by Amazon Web Services (AWS), and APIs of the DXC Assure Platform. Enabling insurers to leverage AI and natural language processing while maintaining their core systems, Assure Smart Apps built with DXC's Assure BPM delivers seamless workflow orchestration, enterprise scalability, and rapid deployment.

"Assure Smart Apps meet insurers where they are, whether they're maintaining heritage systems, extending capabilities, or transforming for the future," said Ray August, President of Insurance Software and Business Process Services at DXC. "This launch represents a major leap forward in how insurers digitize and automate every step of their business processes. Our modular approach provides the flexibility to innovate at their own pace, without disrupting critical operations or existing investments."

Assure Smart Apps are purpose-built with features to address today's most common insurance challenges facing brokers, customers, and advisors:

Self-service capabilities: Allows customers, brokers, and advisors to make their own updates on the platform and change information as needed.
Customer support: Equips customers with personal insurance concierge accessible from their mobile device, using AI-driven insights to provide real-time support.
AI insights: AI-enabled dashboards draw from previously arranged contracts to generate intelligent insights and speed up the decision-making process.
Leverage existing systems: Assure Smart Apps can be built and deployed quickly, working with existing DXC solutions to minimize disruption.
DXC's partnership with ServiceNow enhances the Assure BPM platform's workflow technology and agentic AI capabilities, ensuring robust performance, scalability, and an approximate 80% reduction in process design time. Smart Apps can be implemented individually or bundled into Smart Solutions—market-ready offerings tailored to specific business needs.

With over 40 years of industry expertise, DXC is a trusted partner of choice for 21 of the top 25 insurers. As a leading provider of core insurance systems, DXC continues to innovate—helping insurers accelerate revenue while reducing complexity and costs across more than 1 billion policies processed on DXC software. 

For more information on DXC's insurance solutions, visit our website.

About DXC Technology
DXC Technology (NYSE: DXC) is a leading global provider of information technology services. We're a trusted operating partner to many of the world's most innovative organizations, building solutions that move industries and companies forward. Our engineering, consulting and technology experts help clients simplify, optimize and modernize their systems and processes, manage their most critical workloads, integrate AI-powered intelligence into their operations, and put security and trust at the forefront. Learn more on dxc.com. 

ServiceNow, the ServiceNow logo, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries.

SOURCE DXC Technology Services, LLC

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

There is a lot of hype with this quantum computing company. But it has a lot of bark and little bite.

Everyone wants to own quantum computing stocks. Companies like IonQ (NYSE: IONQ) are up hundreds of percent in the last year, with the aforementioned stock now at a market cap of $25 billion while generating less than $100 million in revenue. Quantum computing could drive huge gains in productivity if the technology is ever commercialized, but today, IonQ is a highly speculative company with little to no business model. This makes it an incredibly risky stock to own.

Here are two stocks not betting on a speculative science fiction future, but creating value in the present. Both Remitly Global (RELY -3.13%) and Portillo's (PTLO -2.76%) will be larger than IonQ in five years' time. Here's why you should add them to your portfolio over any quantum computing stock.

Remitly's disruptive opportunity
Remitly Global has moved in the opposite direction from IonQ in 2025. Shares of the remittance provider are off 42% from highs set earlier in 2025, while IonQ is up 78% year to date (YTD) and just reached a new all-time high.

Investors are nervous about Remitly because of the immigration crackdown in the United States, which may reduce cross-border payments from the United States to Mexico and other Latin American countries. This is Remitly's core business as a mobile disruptor to the legacy players, such as Western Union. Fears are also rising due to a new tax on remittance payments, although it is just a 1% tax and likely not to greatly impact payment flows.

Despite these worries, Remitly has posted strong growth throughout 2025. Revenue was up 34% year over year last quarter, with 40% growth in send volume. Not only is Remitly completely disregarding immigration fears for remittance demand, but it is also taking a ton of market share from legacy players due to its low fees and easy-to-use mobile application.

What's more, Remitly is starting to get profitable. On $1.46 billion in trailing revenue, the business generated an earnings before interest and taxes (EBIT) of $27 million, with plenty of room to increase its operating leverage over time. Compare that to IonQ with minimal revenue and huge operating losses, and Remitly looks like a company that should have a larger market cap than any quantum computing stock.

Image source: Getty Images.

Portillo's expansion plans
Portillo's is a restaurant chain that sells Chicago-style street food, such as hot dogs and Italian beef sandwiches. It has begun to expand to other markets such as Texas and Florida with average success, as some of its restaurant volumes have been hit by a broad slowdown in consumer spending at restaurants in 2024 and 2025.

Despite this, Portillo's is poised to grow substantially in the years ahead. It is planning to slowly grow its presence in new states around the country, bringing this beloved Chicago brand to a national stage. Last quarter, Portillo's posted just 3.6% annual revenue growth, but that is due to the fact that its new store openings are going to be weighted to the back half of 2025. With the company planning to have just around 100 restaurant locations at the end of this year, there is still a huge runway for the concept to expand to new metropolitan areas in the United States.

Portillo's has a market cap of just $464 million today. Investors may look at this market capitalization compared to IonQ and think it is impossible for the restaurant operator to surpass the $25 billion stock within five years. But let's truly compare the underlying financials to show why IonQ is grossly overvalued at its current price.

Over the last 12 months, Portillo's generated $65 million in EBIT on $728 million in revenue. IonQ generated just $53 million in revenue and lost $351 million (it has never been profitable). Portillo's may not surpass a $25 billion market cap in five years, but it will be larger than IonQ because IonQ does not deserve anything close to a $25 billion valuation.

Buy Remitly and Portillo's. Avoid IonQ and other quantum computing stocks. Your portfolio will thank you five years from now.

Brett Schafer has positions in Remitly Global. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Asian markets had a rocky start to the week as fresh Trump tariff threats rekindled worries about a U.S.-China trade war, sparking a selloff across regional indexes.

The brands people consume year-round can make excellent income investments.

Some of the best income investments are the stocks of brands people buy every day in the grocery store. People have been drinking Coca-Cola (KO 1.02%) and eating Hershey (HSY -0.19%) chocolate for over 100 years, and that's not likely going to change. Here's why these top dividend stocks are solid buys right now.

Image source: Getty Images.

1. Coca-Cola
Coca-Cola owns a large portfolio of beverage brands that generate consistent revenue and profits, which fund growing dividend payments. Despite economic hurdles with inflation and choppy consumer spending trends over the past few years, the stock has returned 21% over the last three years and currently offers an attractive forward dividend yield of 3%.

People are not going to stop consuming orange juice, water, coffee, tea, energy beverages, and carbonated soft drinks. Coca-Cola owns top brands across all these categories. This provides opportunities across different occasions to generate sales.

Coca-Cola reported a 1% decline in unit case volume last quarter, reflecting the weak consumer spending trends it has dealt with recently. But higher selling prices drove a 5% year-over-year increase in adjusted (non-GAAP) revenue.

Its strong brands generate healthy margins that support the dividend. Coca-Cola generated $12 billion in net income on $47 billion of revenue over the last year. Through the first half of 2025, it paid out over $2.2 billion in dividends. Its full-year payout ratio is typically around 75% of earnings per share.

After increasing its quarterly dividend by 5% in March to $0.51, Coca-Cola has now increased its dividend for 63 consecutive years -- a testament to the strength of its brands and business strategy.

Investors can expect Coca-Cola to grow its adjusted earnings per share around 8% annually over the long term, which is consistent with management's goal. Combining this earnings growth with a 3% yield should put the total annualized return around 11%.

2. Hershey
Record-high cocoa prices and the recent tariffs on cocoa imports have hurt Hershey's earnings and stock performance. However, with the stock trading 29% below its previous peak (at the time of this writing) and offering a high yield, this is a great time to build a position.

Despite higher operating costs, Hershey is still profitable. Management cited healthy momentum in the business, with adjusted net sales (excluding currency changes) up 26% year over year. While adjusted earnings were down 5%, the company generated $1.6 billion in free cash flow and paid 65% of that in dividends over the last year.

In addition to its namesake brand, Hershey owns several recognizable candy brands like Twizzlers and Reese's. It has also expanded into snacks like Skinny Pop. Management noted that solid execution at driving sales is leading to market share gains in the U.S. confectionery and salty snacks markets.

Spikes in commodity prices have a way of working themselves out in the long run. But even with those higher costs, management has taken steps to mitigate higher commodity costs by raising prices and improving efficiency in the business. This will allow the business to emerge more profitable down the road once cocoa prices settle.

With cocoa prices recently coming down, this could be a great time to buy shares. The quarterly dividend is $1.37, bringing the forward yield to 2.85%. It has rarely offered a yield this high in the last 30 years.

Wall Street analysts believe Hershey will never grow earnings again, but this shows recency bias with recent headwinds and is unrealistic for this iconic chocolate brand. The stock may remain volatile in the near term, but investors should expect the business to continue paying dividends and rewarding shareholders for potentially decades to come.

John Ballard has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hershey. The Motley Fool has a disclosure policy.

October 13, 2025 01:00 ET

 | Source:

F. Hoffmann-La Roche Ltd

Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 30 abstracts across more than 10 cancer types at the European Society for Medical Oncology (ESMO) Congress 2025, held 17-21 October 2025 in Berlin, Germany. The data underscore Roche’s commitment to deliver transformative medicines for some of the most challenging cancer types, including breast cancers, lung cancers, gastrointestinal and genitourinary cancers.

Key presentations include:

Giredestrant: Primary results from the phase III evERA Breast Cancer study, the first positive head-to-head phase III trial investigating a selective oestrogen receptor (ER) degrader-containing regimen versus a standard of care combination in the post-cyclin-dependent kinase inhibitor setting for people with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.1,2 The study met both co-primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival in both the intention-to-treat and ESR1-mutated populations.3 Data will be presented as a late-breaking oral abstract. Tecentriq: Results from the IMvigor011 trial, the first global phase III study pioneering a circulating tumour DNA (ctDNA)-guided approach to post-surgery treatment in muscle-invasive bladder cancer (MIBC).4 Topline results show that people who had detectable ctDNA and were treated with Tecentriq® (atezolizumab) had statistically significant and clinically meaningful improvements in disease-free survival (DFS) and overall survival (OS).5 Data will be presented as part of the Presidential Symposium.Alecensa: Final OS data from the pivotal ALEX study of Alecensa® (alectinib).6 Alecensa is an established first-line treatment and a standard of care for people with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).7-9 Data will be presented as a late-breaking oral abstract and published simultaneously in the Annals of Oncology.Alecensa: Updated results from the phase III ALINA study, reinforcing the role of adjuvant Alecensa as the standard of care for patients with resected ALK-positive NSCLC.10 After a median follow-up of approximately four years, Alecensa DFS data compared with chemotherapy will be presented.10 Overview of key presentations featuring Roche medicines:

Medicine Abstract title Abstract number/presentation details Breast cancer Giredestrant Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial #LBA16 late-breaking oral Proffered paper session 1: Breast cancer, metastatic

Saturday 18 October 2025

10:15-10:25 CEST

Preoperative window-of-opportunity study with giredestrant or tamoxifen (tam) in premenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) and Ki67≥10% early breast cancer (EBC): the EMPRESS study (IIS: MEDSIR)* #294MO mini oral Mini oral session: Breast cancer, early stage

Sunday 19 October 2025

10:50-10:55 CEST

Giredestrant plus Itovebi™ (inavolisib) Interim analysis of giredestrant (GIRE) + inavolisib (INAVO) in MORPHEUS breast cancer (BC): A phase Ib/II study of GIRE treatment (rx) combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC) #508P poster Poster session: Breast cancer, metastatic

Monday 20 October 2025

12:00-17:30 CEST

Itovebi™ phase I/Ib trial of inavolisib (INAVO) + pertuzumab (P) + trastuzumab (H) for
PIK3CA-mutated (mut), HER2-positive advanced breast cancer (HER2+ aBC) #548P poster Poster session: Breast cancer, metastatic

Monday 20 October 2025

12:00-17:30 CEST

Genitourinary cancer Tecentriq® (atezolizumab) IMvigor011: a phase III trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer #LBA8 late-breaking oral Presidential Symposium III

Monday 20 October 2025

16:30-16:42 CEST

Lung cancer Alecensa® (alectinib) Final overall survival (OS) and safety analysis of the phase III ALEX study of alectinib vs crizotinib in patients with previously untreated, advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC) #LBA73 late-breaking oral Proffered paper session: NSCLC metastatic

Friday 17 October 2025

17:06-17:16 CEST

Updated results from the phase III ALINA study of adjuvant alectinib vs chemotherapy (chemo) in patients (pts) with early-stage ALK+ non-small cell lung cancer (NSCLC) #1787MO mini oral Mini oral session 2: Non-metastatic NSCLC

Monday 20 October 2025

14:50-14:55 CEST

Tecentriq Patterns of disease progression (PD) and efficacy associated with tumour burden from
the phase III IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L)
maintenance treatment (tx) in ES-SCLC #2762MO mini oral Mini Oral session 1: Non-metastatic NSCLC

Saturday 18 October 2025

17:15-17:20 CEST

Gastrointestinal cancer Tecentriq   (IIS: NCI, Alliance)**

Clinical outcome of patients (pts) with sporadic vs Lynch syndrome-related stage III colon carcinoma (CC) with deficient mismatch repair (dMMR) treated in a randomized trial of adjuvant FOLFOX alone or combined with atezolizumab (atezo; anti-PD-L1) #752P poster Poster session: Colorectal cancer

Sunday 19 October 2025

Divarasib Single-agent divarasib experience in patients with KRAS G12C-positive pancreatic adenocarcinoma (panc), cholangiocarcinoma (cholangio), and other solid tumors #927MO mini oral Mini oral session: Developmental therapeutics

Friday 17 October 2025

17:00-17:05 CEST

* Investigator Initiated Study (IIS). The study is sponsored by MEDSIR and supported by Genentech, a member of the Roche Group.
** Investigator Initiated Study (IIS). The study is sponsored by the National Cancer Institute (NCI), conducted by the Alliance for Clinical Trials in Oncology and supported by Genentech, a member of the Roche Group.

About Roche in oncology
For over 60 years, Roche has delivered transformative medicines and diagnostics, redefining the treatment of some of the most challenging cancers. Driven by a vision of a future where cancer can be cured, we focus our efforts on cancers with the highest societal impact and where we bring deep expertise, including breast, lung, and blood cancers, while pursuing breakthrough innovation in other areas of unmet need. Our pipeline features a diverse array of modalities, from small molecules and antibodies to next-generation ADCs and allogeneic CAR T-cell therapies. By advancing best-in-class precision medicine, pioneering novel combinations, and leveraging key technologies and partnerships, Roche tackles oncology's toughest challenges with the goal of delivering life-changing outcomes for people with cancer.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Mayer E, et al. Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial. To be presented at: ESMO Congress; 2025 Oct 17-21; Berlin, Germany. Abstract #LBA16.
[2] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) [Internet; cited 2025 October]. Available from: https://clinicaltrials.gov/study/NCT05306340.
[3] Roche. Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer [Internet; cited 2025 October]. Available from: https://www.roche.com/media/releases/med-cor-2025-09-22.
[4] Powles T, et al. IMvigor011: a phase 3 trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer. To be presented at: ESMO Congress; 2025 Oct 17-21; Berlin, Germany. Abstract #LBA8.
[5] Natera. IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit [Internet; cited 2025 October]. Available from: https://www.natera.com/company/news/imvigor011-bladder-cancer-trial-achieves-positive-results-with-signatera-strongly-predicting-adjuvant-immunotherapy-benefit/https://www.natera.com/company/news/imvigor011-bladder-cancer-trial-achieves-positive-results-with-signatera-strongly-predicting-adjuvant-immunotherapy-benefit/.
[6] Mok T, et al. Final overall survival (OS) and safety analysis of the phase 3 ALEX study of alectinib vs crizotinib in patients with previously untreated, advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC). To be presented at: ESMO Congress; 2025 Oct 17-21; Berlin, Germany. Abstract #LBA73.
[7] Peters S, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(9); 829-838.
[8] Mok T, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056-1064.
[9] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer v.5.2024.
[10] Dziadziuszko R, et al. Updated results from the phase III ALINA study of adjuvant alectinib vs chemotherapy (chemo) in patients (pts) with early-stage ALK+ non-small cell lung cancer (NSCLC). To be presented at: ESMO Congress; 2025 Oct 17-21; Berlin, Germany. Abstract #1787MO.

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: [email protected]

Hans Trees, PhD
Phone: +41 79 407 72 58 Sileia Urech
Phone: +41 79 935 81 48 Nathalie Altermatt
Phone: +41 79 771 05 25 Lorena Corfas
Phone: +41 79 568 24 95 Simon Goldsborough
Phone: +44 797 32 72 915 Karsten Kleine
Phone: +41 79 461 86 83 Kirti Pandey
Phone: +49 172 6367262 Yvette Petillon
Phone: +41 79 961 92 50 Dr Rebekka Schnell
Phone: +41 79 205 27 03   Roche Investor Relations

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: [email protected] Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: [email protected] Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: [email protected]   Investor Relations North America

Media & Investor Release ESMO 2025 Curtain Raiser English

Attachments

Media & Investor Release ESMO 2025 Curtain Raiser English...

SummaryMirion Technologies is rated a buy, supported by strong nuclear power demand and a robust, recurring revenue model.The Paragon acquisition doubles MIR's SMR exposure, enhances its product portfolio, and strengthens its position in next-generation nuclear technology.MIR targets 30% EBITDA margins by 2028, driven by operating leverage, business mix shift, and operational restructuring.Valuation supports ~20% upside, with multi-decade nuclear tailwinds and Paragon integration providing clear growth visibility and margin expansion. Monty Rakusen/DigitalVision via Getty Images

Investment Action I give a buy rating for Mirion Technologies (NYSE:MIR) as I see a long, structural growth runway ahead, driven by the global nuclear power demand. The combination of a powerful demand tailwind, a strong market

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Bitcoin’s (CRYPTO: BTC) flash crash late Friday, which happened outside of regular trading hours, has reignited debate about the operating hours of spot BTC exchange-traded funds, particularly the iShares Bitcoin Trust ETF (NASDAQ:IBIT).

The apex cryptocurrency collapsed from $116,000 to under $110,000 within minutes after President Donald Trump threatened 100% tariffs on China in response to “aggressive stance” on export controls.

The sudden spike caught traders off-guard, triggering over $19 billion in liquidations, the largest single-day wipeout in cryptocurrency history.”

See Also: Bitcoin (BTC) Price Predictions: 2025, 2026, 2030

ETF Investors Left In The Lurch?The crash fueled concerns about the lack of 24/7 trading of BTC exchange-traded funds, which have become a popular vehicle for institutional investors, Forbes reported, quoting Tommy Doyle, global head of client management at Xapo Bank.

"The extreme volatility in the price of Bitcoin overnight highlights why institutional investors increasingly view access to 24/7 liquidity as essential to prudent risk management,” Doyle said.

Notably, these ETFs, including the nearly $100 billion IBIT, are bound by stock trading hours, which prevents investors from responding to weekend price shifts.

“Whilst Bitcoin ETFs remain bound by traditional market trading hours, institutional investors with direct bitcoin accounts can continue to access liquidity and risk manage their bitcoin exposure throughout the weekend, especially relevant amid recent seismic price moves,” Doyle told Forbes.

It’s worth noting that Robinhood allows trading from 8 p.m. ET on Sunday until 8 p.m. ET on Friday, with some restrictions.

BlackRock’s IBIT ETF is the largest cryptocurrency-based investment fund currently in operation, with assets under management totaling almost $94 billion, according to SoSo Value.

Overall, BTC ETFs reported net inflows exceeding $2.70 billion for the week ended Oct.10.

Price Action: At the time of writing, BTC was trading at $115,645.17, rebounding 4.33% in the last 24 hours, according to data from Benzinga Pro.

IBIT shares closed 3.74% lower at $66.17 during Friday’s regular trading session. Year-to-date, the stock has gained 24%.

Benzinga’s proprietary Edge Rankings show Momentum as the strongest category for IBIT at 88.34/100. To see how IBIT stock ranks for Value, Growth and Quality, click here.

Read Next: 

Weekend Roundup: Bitcoin Jesus’ Tax Evasion Case, Gold’s Rally And More Crypto News
Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.

Photo Courtesy: Arsenii Palivoda on Shutterstock.com

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

IoTeX plans to launch a token buyback program and strengthen exchange liquidity after a temporary market maker issue caused irregular price movements.

Summary

IoTeX confirms Binance “zero price” was a UI glitch tied to a market maker issue.
Foundation to launch buybacks and liquidity programs to stabilize trading.
IOTX price recovered to as users praised the team’s transparent handling.

IoTeX has announced a token buyback program and new liquidity partnerships following a market maker incident that briefly disrupted trading and sent its price to near-zero on Binance.

In an Oct.13 post on X, IoTeX (IOTX) confirmed that the “zero price” event on Oct. 10–11, 2025, was linked to a third-party market maker malfunction and not a protocol exploit. The network’s core services — including ioPay wallet, ioTube bridge, and DePINscan — remained fully operational, and no user funds were affected.

Zero Was Not Reality.

@binance has clarified that the “0.0000” $IOTX price shown on Oct 10 was due to UI display and system issue, not real market activity. Price charts are being corrected — the first step toward full resolution. 💪

We stand firmly with every community… https://t.co/NpEV965oUw

— IoTeX (@iotex_io) October 13, 2025

Incident traced to liquidity glitch, not exploit
The team clarified that Binance had already addressed the issue, confirming it was a user interface display problem rather than an actual market crash. In its statement, Binance said the “0.0000” IOTX price displayed during the event resulted from reduced decimal precision on certain trading pairs, combined with extreme volatility that briefly triggered long-standing limit orders.

Binance’s review also showed that its spot and futures engines functioned normally throughout the market-wide sell-off. The exchange completed compensation for users affected by de-pegging or delayed redemptions within 24 hours, totaling roughly $283 million in payouts across multiple assets.

IoTeX launches recovery plan
Following the clarification, IoTeX said it will work closely with centralized exchanges and market-making partners to boost liquidity and prevent similar disruptions. In an effort to boost long-term holders’ confidence, the foundation also announced token buybacks and community reward programs.

The event caused IOTX to fall around 15–20%, from $0.015 to $0.0125, amplifying an already steep 42% weekly decline tied to broader market weakness. Trading volume surged past $24 million in 24 hours, but the token stabilized around $0.013 by Oct. 13.

At first, the community became cautious, with some traders comparing the incident to other projects. IoTeX’s openness and quick communication, however, contributed to the restoration of trust. The official account and co-founder Raullen Chai’s posts emphasized that “no user funds were at risk,” and users later commended the team for their prompt action.

With more than 100 projects and 40 million connected devices on its network, the incident comes as IoTeX is making a bigger shift toward AI-integrated DePIN infrastructure.. Deflationary mechanisms like Burndrop continue to reduce circulating supply, reinforcing IOTX’s positioning in the expanding AI-DePIN narrative.

Bitcoin price corrected losses and traded above the $114,000 level. BTC is now struggling and might face hurdles near the $116,000 level.

Bitcoin started a recovery wave above the $113,500 resistance level.
The price is trading below $116,000 and the 100 hourly Simple moving average.
There is a bearish trend line forming with resistance at $119,500 on the hourly chart of the BTC/USD pair (data feed from Kraken).
The pair might continue to move down if it trades below the $113,500 zone.

Bitcoin Price Starts Recovery
Bitcoin price started a recovery wave after a massive liquidation event below $110,000. BTC recovered above the $111,500 and $112,000 resistance levels.

The price climbed above the 50% Fib retracement level of the sharp decline from the $123,750 swing high to the $100,000 low. The bulls even pushed the price above the $113,500 resistance level. However, there are many hurdles on the upside.

Bitcoin is now trading below $116,500 and the 100 hourly Simple moving average. Besides, there is a bearish trend line forming with resistance at $119,500 on the hourly chart of the BTC/USD pair.

Immediate resistance on the upside is near the $116,000 level. The first key resistance is near the $116,250 level. The next resistance could be $118,000 and the 76.4% Fib retracement level of the sharp decline from the $123,750 swing high to the $100,000 low.

Source: BTCUSD on TradingView.com
A close above the $118,000 resistance might send the price further higher. In the stated case, the price could rise and test the $119,500 resistance and the trend line. Any more gains might send the price toward the $120,000 level. The next barrier for the bulls could be $122,500.

Another Decline In BTC?
If Bitcoin fails to rise above the $116,000 resistance zone, it could start a fresh decline. Immediate support is near the $114,000 level. The first major support is near the $113,500 level.

The next support is now near the $113,500 zone. Any more losses might send the price toward the $112,500 support in the near term. The main support sits at $110,500, below which BTC might struggle to recover in the short term.

Technical indicators:

Hourly MACD – The MACD is now gaining pace in the bullish zone.

Hourly RSI (Relative Strength Index) – The RSI for BTC/USD is now above the 50 level.

Major Support Levels – $113,500, followed by $112,500.

Major Resistance Levels – $116,000 and $118,000.

Bitcoin Core developers saw a mixed reaction from the Bitcoin community as they announced the release of their v30 update, bringing forward a host of node-related changes to architecture, performance, and security.

The key changes brought forward in Bitcoin Core 30.0 are the introduction of optional encrypted connections between nodes for better privacy and the increase of the OP_RETURN data limit within Bitcoin Core software from 80 to 100,000 bytes, enabling a significantly larger amount of non-financial data to be embedded in Bitcoin transactions.

“With the release of this new major version, versions 27.x and older are at ‘End of Life’ and will no longer receive updates,” the Sunday announcement reads. 

The key changes of Bitcoin Core v30. Source: Bitcoin Core While the update also included bug fixes, performance improvements and changes to fee rates, the biggest issue to stir debate in the community is the increase of the OP_Return limit.

Such a huge shift in the data limit enables the development of more sophisticated and data-hungry decentralized applications on the network, but has angered Bitcoin purists who argue that the network should be used only for financial transactions.

Community pushback against Bitcoin Core v30. Source: XNew blocksize warsWhile this wasn’t a protocol change, the current debate sparks memories of the block size wars of 2017, which ultimately led to a Bitcoin hard fork in Bitcoin Cash. 

Some see the update as a good thing, such as Ark Labs Ecosystem Lead Alex Bergeron, who said via X on Friday that he intends “to use all of the additional OP_Return space and WILL use it to make Bitcoin more like Ethereum, except better.” 

CasaHODL co-founder Jameson Lopps is fully behind Bitcoin Core v30. Source: Jameson Lopp While Satoshi Labs co-founder Pavol Rusnak also stated yesterday that he was opting for Bitcoin Core v30 due to having “great development team, peer-reviewed code,” and “sane engineering decisions.”

Pavol Rusnak is jumping on Bitcoin Core v30. Source: Pavol Rusnak Others were not so optimistic, arguing that it goes against Bitcoin’s fundamental principles of being a peer-to-peer electronic cash system and could lead to blockchain bloat, increased node operation costs and legal issues. 

One workaround that a significant number of node operators have already been utilising is the alternative node software known as “knots,” as it enables them to enforce strict data size limits, such as 80 bytes, on transactions.  

“As a (hopefully) temporary measure, run Knots. I strongly recommend not upgrading to Core v30,” noted pioneer cryptographer Nick Szabo via X last week.

Earlier this month, Szabo raised concerns about the legal implications of the data limit increase, as node operators run the risk of hosting “illegal data.”

“Without adding safeguards to allow archival node operators to non-disruptively delete illegal content for which they will often be held criminally liable,” he noted via X on Oct. 2.  

The founder of knots, Luke Dashjr, has not commented on the update since it went live; however, he has been critical of the latest Bitcoin Core update.

Luke Dashjr is highlighting concerns with Bitcoin Core v30. Source: Luke Dashjr Data shows that a significant number of node operators are utilising Knots software, with data from BitRef indicating that there are currently 5,114 Knots nodes, representing 21.48% of all Bitcoin nodes. 

Magazine: Bitcoin’s ‘macro whiplash,’ Shuffle suffers data breach: Hodler’s Digest, Oct. 5 – 11

Binance has issued an update clarifying that several altcoins on its exchange did not actually crash to zero during Friday’s crypto market turmoil. The world’s largest cryptocurrency exchange confirmed that a “display issue,” not an actual price collapse, caused certain tokens — including IoTeX (IOTX), Cosmos (ATOM), and Enjin (ENJ) — to appear as if they had fallen to $0.

According to Binance’s announcement, “Certain trading pairs, such as IOTX/USDT, recently reduced the number of decimal places allowed for minimum price movement, causing the displayed prices in the user interface to be zero.” The exchange emphasized that this was purely a visual glitch and that trading activity was not affected.

The incident came amid one of the most dramatic sell-offs in crypto history, which wiped out up to $20 billion in leveraged positions within 24 hours — marking the largest liquidation event ever recorded. This sparked widespread panic, with traders initially believing that Binance had suffered a catastrophic failure.

Adding to the speculation, some analysts suggested that Binance may have been the target of a coordinated exploit. Crypto trader ElonTrades theorized that attackers took advantage of Binance’s “Unified Account” system, which relies on internal oracle data. The exploit allegedly caused massive price discrepancies, particularly impacting Ethena’s synthetic dollar (USDe), which briefly depegged to $0.65.

Binance has since announced $283 million in compensation for users affected by the event, while also confirming plans to shift to external oracle data sources by October 14. Despite the company’s reassurances, Crypto.com CEO Kris Marszalek has called for regulatory reviews of centralized exchanges involved in the crash.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

XRP has emerged as one of the standout performers in the ongoing 2025 cryptocurrency bull market. While much of the market focuses on Bitcoin, Ethereum, and BNB, XRP's price action has quietly outpaced many of its peers.

By

PYMNTS
 | 
October 12, 2025

 | 

The third-largest stablecoin reportedly lost its dollar peg briefly amid a wider market downturn.

USDe, a “synthetic dollar” from cryptocurrency project Ethena, fell to 65 cents against the U.S. dollar on Binance’s exchange, Bloomberg News reported Saturday (Oct. 11). The coin is designed to maintain a price near to that of the dollar, and regained that status following an initial sell-off, the report added.

“Our team is currently conducting a thorough review of the impacted users, the details surrounding these liquidations, and the appropriate compensation measures,” Binance wrote in a blog post about USDe and two other tokens that lost their pegs.

This came as the price of crypto tumbled following President Donald Trump’s announcements of a new 100% tariff on China, wiping out more than $19 billion in crypto investments and leading to more than 1.6 million traders liquidated.

China has called the new tariffs hypocritical and defended its limits on exports of rare earth elements and equipment, but fell short of placing new tariffs of its own on American products.

Trump on Sunday (Oct. 12) seemed to downplay the dispute on his Truth Social platform.

Advertisement: Scroll to Continue

With a market value of $14 billion, USDe is the third-largest stablecoin after Tether and Circle. However, the Bloomberg report noted that its price fluctuations, while short-lived, were enough to trigger concerns among investors. Ethena Labs wrote in a post on X that the coin remains over-collateralized.

“Even a brief stablecoin depeg can shake the market,” said Rachael Lucas, analyst at BTC Markets. “Traders rely on them for liquidity, lending and collateral, so any loss of confidence can trigger liquidations and spill into wider crypto volatility.”

In other stablecoin news, PYMNTS wrote last week about the way the emerging goal of these tokens seems to be “to make ‘crypto’ disappear as a standalone concept.”

“Just as few people today think about TCP/IP when they send an email, few will think about stablecoins when they make an instant international payment,” that report said. “The technology will recede into the background, embedded in the pipes of everyday finance.”

An example of that embedding, the report added, can be seen in the news that Coinbase and Mastercard are in advanced negotiations to acquire BVNK, a FinTech offering enterprise-grade stablecoin payments infrastructure.

“Acquiring BVNK gives the buyer not just software but connectivity to banks, payment networks, and enterprise clients already using BVNK’s rails,” PYMNTS wrote. “BVNK claims to process over $20 billion annually and supports clients including Worldpay, Flywire, and dLocal.”

XRP appears to be entering a critical recovery phase as multiple technical and on-chain indicators suggest potential for a strong rebound. Recently, XRP dipped below its 200-day moving average near $2.06 but quickly reclaimed the level with significant trading volume. This “flush and reclaim” formation often signals capitulation by sellers and the entry of major buyers absorbing panic-driven sell-offs. Historically, similar XRP price patterns have preceded short-term rallies ranging from 30% to 50%, aligning with a potential move toward the $1 mark if bullish momentum continues.

Another strong bullish signal is XRP’s Relative Strength Index (RSI), which currently hovers around 27 — a level that indicates highly oversold conditions. In past market cycles, RSI reversals from below 30 have triggered multi-week recoveries as short sellers liquidated their positions and fresh liquidity entered the market. This pattern points toward renewed investor confidence and a possible price rebound.

Beyond technicals, on-chain data also supports a recovery narrative. The recent surge in XRP Ledger transactions and payment volumes, even amid price declines, suggests a strengthening network utility. Such divergence between price and blockchain activity often precedes renewed speculative optimism, an essential driver for crypto market rebounds.

From a macroeconomic perspective, global market fears linked to tariff tensions seem to be easing, which could stabilize overall sentiment. Combined with Bitcoin’s relative strength, this environment may provide XRP with additional tailwinds for recovery.

While trader sentiment remains cautious, the setup for a potential breakout toward $1 appears realistic. However, confirmation above the $2.8–$3.0 range would be crucial for validating a sustained bullish reversal.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

In brief
Bitcoin slid from $121,000 to $109,000 in about seven hours Friday. Ethereum hit $3,686 and Solana hovered above $173, per CoinGecko.
Liquidations neared $20 billion for the day, including roughly $16.7 billion in longs, after an hour that wiped almost $7 billion.
Stocks fell alongside crypto, with the Nasdaq falling 3.6%, S&P 500 down 2.7%, while the Dow slipped 1.9%.
The crypto market has begun to claw back losses following a sell-off that resulted in one of the worst liquidation events in its history.

On Friday, Bitcoin fell from $121,000 to as low as $109,000 over a seven-hour period, erasing all gains made from an early “Uptober” rally. Ethereum dipped to a low of $3,686 while Solana touched just above $173, CoinGecko data shows.

The volatile trading session triggered a “flash crash of liquidations,” wiping almost $7 billion across all markets within one hour, with $5.5 billion coming from longs, Sean Dawson, head of research at on-chain options platform Dervie, told Decrypt.

When the dust settled, nearly $20 billion in liquidations across all digital assets had been wiped out in a single day on Friday, with $16.7 billion in long positions making up the majority, CoinGlass data shows.

Overall, it marked “the largest single-day wipeout in crypto history,” Dawson said.

Stocks were also hard hit, with the Nasdaq dipping 3.6%, the S&P 500 down 2.7% and the Dow falling 1.9%. 

The sell-off in stocks and crypto followed President Trump's announcement that he was canceling a planned meeting with Chinese President Xi Jinping and had ordered a “massive increase” in tariffs on Chinese imports—a move he acknowledged could be “potentially painful” for Americans.

Trump’s tariff warning came after Beijing moved to curb exports of rare earths and critical minerals, escalating tensions between the world’s two largest economies. 

By the weekend, China appeared to soften its stance, with analysts suggesting the market rout may have been fueled by a brief geopolitical overreaction.

“What we’re seeing is a textbook relief rally,” Dean Serroni, CEO of crypto investment manager Merkle Tree Capital, told Decrypt.

“Ethereum’s 11% surge is pure short-covering and mean reversion after the market overreacted to Trump’s tariff bombshell,” he said.

Serroni pointed to “thin” selling pressure amid a reset to open interest across derivatives markets after volatility spiked on “overleveraged derivatives traders.”

Bitcoin is up 5% on the day to $115,100 while Ethereum is up 10.5% to $4,138, CoinGecko data shows. Meanwhile, major altcoins including Solana, BNB, and Dogecoin are up 12%, 16.5% and 11.4%, respectively.

“This rout was a geopolitical knee-jerk, not a structural break,” Serroni said.

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

Block Inc. (NYSE: SQ) is expanding its Square platform to make Bitcoin a seamless part of everyday business operations. With Square Bitcoin, merchants can now manage both traditional and crypto finances in a single ecosystem, enabling fee-free Bitcoin payments and automated Bitcoin conversions.

As bitcoin and ethereum extend their slide, Peter Schiff warns of a potential bitcoin plunge to $75K, intensifying bearish sentiment despite optimism over adoption and blockchain growth.